WHAT IS CLAIMED IS:

1. A composition comprising:

(a) a vector comprising a plasmid that encodes at least one viral antigen; and

(b) a vector comprising a CD1d-recognized antigen; and

(c) at least one pharmaceutically acceptable carrier,

wherein at least one of vector (a) and vector (b) is an intact, bacterially-derived minicell or killed bacterial cell.

2. The composition of claim 1, wherein vector (a) is a first intact, bacterially derived minicell or killed bacterial cell, and vector (b) is a second intact, bacterially derived minicell or killed bacterial cell.

3. The composition of claim 1, wherein vector (a) and vector (b) are the same intact, bacterially derived minicell or killed bacterial cell, comprising the CD1d-recognized antigen and the plasmid that encodes at least one viral antigen.

4. The composition of claim 1, wherein one of vector (a) and vector (b) is not an intact, bacterially derivd minicell or killed bacterial cell and the other of vector (a) and vector (b) is an intact, bacterially derived minicell or killed bacterial cell.

5. The composition of any one of claims 1-4, wherein the viral antigen comprises or characterizes a virus selected from the group consisting of an Alphacoronavirus; a Colacovirus such as Bat coronavirus CDPHE15; a Decacovirus such as Bat coronavirus HKU10 or Rhinolophus ferrumequinum alphacoronavirus HuB-2013; a Duvinacovirus such as Human coronavirus 229E; a Luchacovirus such as Lucheng Rn rat coronavirus; a Minacovirus such as a Ferret coronavirus or Mink coronavirus 1; a Minunacovirus such as Miniopterus bat coronavirus 1 or Miniopterus bat coronavirus HKU8; a Myotacovirus such as Myotis ricketti alphacoronavirus Sax-2011; a nyctacovirus such as Nyctalus velutinus alphacoronavirus SC-

2013; a Pedacovirus such as Porcine epidemic diarrhea virus or Scotophilus bat coronavirus 512; a Rhinacovirus such as Rhinolophus bat coronavirus HKU2; a Setracovirus such as Human coronavirus NL63 or NL63-related bat coronavirus strain BtKYNL63-9b; a Tegacovirus such as Alphacoronavirus 1; a Betacoronavirus; a Embecovirus such as Betacoronavirus 1, Human coronavirus OC43, China Rattus coronavirus HKU24, Human coronavirus HKU1 or Murine coronavirus; a Hibecovirus such as Bat Hp-betacoronavirus Zhejiang2013; a Merbecovirus such as Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus (MERS-CoV), Pipistrellus bat coronavirus HKU5 or Tylonycteris bat coronavirus HKU4; a Nobecovirus such as Rousettus bat coronavirus GCCDC1 or Rousettus bat coronavirus HKU9, a Sarbecovirus such as a Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome coronavirus (SARS-CoV) or Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19); a Deltacoronavirus; an Andecovirus such as Wigeon coronavirus HKU20; a Buldecovirus such as Bulbul coronavirus HKU11, Porcine coronavirus HKU15, Munia coronavirus HKU13 or White-eye coronavirus HKU16; a Herdecovirus such as Night heron coronavirus HKU19; a Moordecovirus such as Common moorhen coronavirus HKU21; a Gammacoronavirus; a Cegacovirus such as Beluga whale coronavirus SW1; and an Igacovirus such as Avian coronavirus.

6. The composition of any one of claims 1-5, wherein the viral antigen is encoded by a polynucleotide comprising the sequence of SARS-CoV-2, or a polynucleotide having at least 80% sequence identity to the polynucleotide comprising the sequence of SARS-CoV-2.

7. The composition of any one of claims 1-5, wherein the viral antigen comprises or is characteristic of human coronavirus 229E, human coronavirus OC43, SARS-CoV, HCoV NL63, HKU1, MERS-CoV, or SARS-CoV-2.

8. The composition of claim 7, wherein the viral antigen comprises or is characteristic of SARS-CoV-2.

9. The composition of claim 8, wherein the plasmid encodes at least one of spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and envelope (E) protein of of SARS-CoV-2.

10. The composition of claim 9, wherein the plasmid encodes the spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein.

11. The composition of any one of claims 1-10, wherein the CD1d-recognized antigen comprises a glycosphingolipid.

12. The composition of any one of claims 1-11, wherein the CD1d-recognized antigen is selected from the group consisting of α-galactosylceramide (α-GalCer), C-glycosidific form of α-galactosylceramide (α-C-GalCer), 12 carbon acyl form of galactosylceramide (β-GalCer), β-D-glucopyranosylceramide (β-GlcCer), 1,2-Diacyl-3-O-galactosyl-sn-glycerol (BbGL-II), diacylglycerol containing glycolipids (Glc-DAG-s2), ganglioside (GD3), gangliotriaosylceramide (Gg3Cer), glycosylphosphatidylinositol (GPI), α-glucuronosylceramide (GSL-1 or GSL-4), isoglobotrihexosylceramide (iGb3), lipophosphoglycan(LPG), lyosphosphatidylcholine (LPC), α-galactosylceramide analog (OCH), threitolceramide, and a derivative of any thereof.

13. The composition of any one of claims 1-12, wherein the CD1d-recognized antigen comprises α-GalCer.

14. The composition of any one of claims 1-13, wherein the CD1d-recognized antigen comprises a synthetic α-GalCer analog.

15. The composition of claim 14, wherein the CD1d-recognized antigen comprises a synthetic α-GalCer analog selected from 6′-deoxy-6′-acetamide α-GalCer (PBS57), napthylurea α-GalCer (NU-α-GC), NC-α-GalCer, 4ClPhC-α-GalCer, PyrC-α-GalCer, α-carba-GalCer, carba-

α-D-galactose α-GalCer analog (RCAI-56), 1-deoxy-neo-inositol α-GalCer analog (RCAI-59), 1-O-methylated α-GalCer analog (RCAI-92), and HS44 aminocyclitol ceramide.

16. The composition of any one of claims 1-15, wherein the CD1d-recognized antigen is an IFNγ agonist.

17. The composition of any one of claims 1-16, wherein the composition is formulated for oral administration, injection, nasal administration, pulmonary administration, or topical administration.

18. A method of treating and/or vaccinating against a viral infection, comprising administering to a subject in need a composition according to any one of claims 1-16.

19. The method of claim 18, wherein the subject:

(a) is suffering from or at risk of developing lymphopenia; and/or

(b) is deemed at risk for severe illness and/or serious complications from the viral infection; and/or

(c) is about age 50 or older, about age 55 or older, about age 60 or older, or about age 65 or older; and/or

(d) suffers from one or more pre-existing conditions selected from the group consisting of diabetes, asthma, a respiratory disorder, high blood pressure, and heart disease; and/or

(e) is immunocompromised; and/or

(f) is immunocompromised due to AIDS, cancer, a cancer treatment, hepatitis, an auto-immune disease, steroid receiving, immunosenescence, or any combination thereof.

20. The method of any one of claims 18-18, wherein administration:

(a) increases the chance of survival following exposure to a coronavirus; and/or

(b) reduces the risk of transmission of coronavirus.

21. The method of claim 20, wherein:

(a) the chance of survival is increased by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, as measured using any clinically recognized technique; and/or

(b) the reduction in risk of transmission is by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, as measured using any clinically recognized technique.

22. The method of any one of claims 18-21, wherein administering is via any pharmaceutically acceptable methods.

23. The method of any one of claims 18-22, wherein the subject is exposed to or is anticipated to be exposed to an individual who is contagious for a coronavirus.

24. The method of claim 23, wherein the individual who is contagious for a coronavirus has one or more symptoms selected from the group consisting of fever, cough, shortness of breath, diarrhea, sneezing, runny nose, and sore throat.

25. The method of any one of claims 18-24, wherein the subject is a healthcare worker, aged 60 years or older, frequent traveler, military personnel, caregiver, or a subject with a preexisting condition that results in increased risk of mortality with infection.

26. The method of any one of claims 18-25, further comprising administering one or more antiviral drugs.

27. The method of claim 26, wherein the one or more antiviral drugs are selected from the group consisting of chloroquine, darunavir, galidesivir, interferon beta, lopinavir, ritonavir, remdesivir, and triazavirin.

28. The method of any one of claims 18-27, wherein the CD1d- recognized antigen induces a Th1 cytokine response in the subject, and optionally wherein the cytokine comprises IFNγ.

29. The method of any one of claims 18-28, wherein:

(a) a first minicell comprising the CD1d- recognized antigen and a second minicell comprising the plasmid encoding at least one viral antigen are administered to the subject simultaneously; and/or

(b) a first minicell comprising the CD1d- recognized antigen and a second minicell comprising the plasmid encoding at least one viral antigen are administered to the subject sequentially; and/or

(c) a first minicell comprising the CD1d- recognized antigen and second minicells comprising the plasmid encoding at least one viral antigen are administered to the subject repeatedly; and/or

(d) a first minicell comprising the CD1d- recognized antigen and second minicells comprising the plasmid encoding at least one viral antigen are administered to the subject at least once a week, twice a week, three times per week, or four times per week.

30. Use of a composition according to any one of claims 1-17 for the manufacture of a medicament, wherein the medicament is useful in treating and/or vaccinating against a viral infection.